AR059127A1 - Terapeutica combinada con anticuerpos anti-egfr y anti-her2 - Google Patents

Terapeutica combinada con anticuerpos anti-egfr y anti-her2

Info

Publication number
AR059127A1
AR059127A1 ARP070100020A ARP070100020A AR059127A1 AR 059127 A1 AR059127 A1 AR 059127A1 AR P070100020 A ARP070100020 A AR P070100020A AR P070100020 A ARP070100020 A AR P070100020A AR 059127 A1 AR059127 A1 AR 059127A1
Authority
AR
Argentina
Prior art keywords
her2
antibody
combined
egfr
cancer
Prior art date
Application number
ARP070100020A
Other languages
English (en)
Inventor
Stephen D Gillies
David Azria
Christel Larbouret
Andre Pelegrin
Original Assignee
Inst Nat Sante Rech Med
Merck Patent Gmbh
Ct Regional De Lutte Contre Le
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
Priority to EP06000107 priority Critical
Application filed by Inst Nat Sante Rech Med, Merck Patent Gmbh, Ct Regional De Lutte Contre Le filed Critical Inst Nat Sante Rech Med
Publication of AR059127A1 publication Critical patent/AR059127A1/es
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37876938&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR059127(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507Comprising a combination of two or more separate antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31Immunoglobulins specific features characterized by aspects of specificity or valency multispecific

Abstract

Uso combinado de anticuerpo anti-EGFR y anticuerpo anti-Her2 para el tratamiento de cáncer; especialmente se refiere al tratamiento combinado mediante anticuerpo monoclonal ômatuzumabö (hmAB 425, EMD 72000) dirigido contra receptores EGF y ôtrastuzumabö (HERCEPTIN«) dirigido contra los receptores HER2. El tratamiento combinado es adecuado para pacientes que sufren cáncer, especialmente en donde HER2 se expresa en baja cantidad, de preferencia cáncer de páncreas. Reivindicacion 1: Una composicion farmacéutica que comprende un anticuerpo anti-EGFR y un anticuerpo anti-HER2 (ErbB2) o sus fragmentos inmunologicamente efectivos en una cantidad efectiva opcionalmente junto con un portador, diluyente o excipiente farmacéutico, en donde el anticuerpo anti-EGFR es mAb 425 murino, quimérico o humanizado (matuzumab), y el anticuerpo anti-HER2 es mAb 4D5 murino, quimérico o humanizado(trastuzumab).
ARP070100020A 2006-01-04 2007-01-03 Terapeutica combinada con anticuerpos anti-egfr y anti-her2 AR059127A1 (es)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP06000107 2006-01-04

Publications (1)

Publication Number Publication Date
AR059127A1 true AR059127A1 (es) 2008-03-12

Family

ID=37876938

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP070100020A AR059127A1 (es) 2006-01-04 2007-01-03 Terapeutica combinada con anticuerpos anti-egfr y anti-her2

Country Status (13)

Country Link
US (2) US20090214541A1 (es)
EP (1) EP1968633B2 (es)
JP (1) JP2009522316A (es)
KR (1) KR20080110987A (es)
CN (1) CN101365486B (es)
AR (1) AR059127A1 (es)
AU (1) AU2006332212B8 (es)
BR (1) BRPI0620888A2 (es)
CA (1) CA2636074A1 (es)
EA (1) EA015173B1 (es)
MX (1) MX2008008564A (es)
WO (1) WO2007076923A1 (es)
ZA (1) ZA200806723B (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT446317T (de) 2001-05-11 2009-11-15 Ludwig Inst For Cancer Res Ltd Spezifische bindungsproteine und ihre verwendung
US20100056762A1 (en) 2001-05-11 2010-03-04 Old Lloyd J Specific binding proteins and uses thereof
DK2059533T3 (da) 2006-08-30 2013-02-25 Genentech Inc Multispecifikke antistoffer
CA2676244C (en) 2007-01-25 2017-01-17 Kwok-Kin Wong Use of anti-egfr antibodies in treatment of egfr mutant mediated disease
JP5618549B2 (ja) 2007-03-15 2014-11-05 ルードヴィッヒ インスティテュート フォー キャンサーリサーチ リミテッド Egfr抗体及びsrc阻害剤を用いる治療方法及び関連製剤
CN101896503B (zh) 2007-08-14 2018-05-22 路德维格癌症研究所有限公司 靶向egf受体的单克隆抗体175及其衍生物和用途
WO2009082485A1 (en) * 2007-12-26 2009-07-02 Vaccinex, Inc. Anti-c35 antibody combination therapies and methods
RU2547596C2 (ru) 2008-09-03 2015-04-10 Дженентек, Инк. Полиспецифические антитела
EP2337800B1 (en) 2008-09-15 2013-10-02 Yeda Research and Development Co. Ltd. Antibody combinations and use of same for treating cancer
US8728479B2 (en) * 2009-03-31 2014-05-20 The Trustees Of The University Of Pennsylvania Antigen-binding proteins comprising recombinant protein scaffolds
WO2011069104A2 (en) * 2009-12-04 2011-06-09 Genentech, Inc. Multispecific antibodies, antibody analogs, compositions, and methods
US8609095B2 (en) * 2010-03-04 2013-12-17 Symphogen A/S Anti-HER2 antibodies and compositions
US9155802B2 (en) 2010-11-01 2015-10-13 Symphogen A/S Pan-HER antibody composition
WO2012156975A1 (en) 2011-05-16 2012-11-22 Yeda Research And Development Co. Ltd. COMBINATIONS OF ANTI ErbB ANTIBODIES FOR THE TREATMENT OF CANCER
EP2844675B1 (en) 2012-05-02 2019-01-02 Symphogen A/S Humanized pan-her antibody compositions
CA2907548A1 (en) 2013-03-13 2014-10-02 University Of Kentucky Research Foundation Methods of administering igg1 antibodies and methods of suppressing angiogenesis
WO2014139131A1 (en) 2013-03-14 2014-09-18 Crown Bioscience, Inc. Use of egfr biomarkers for the treatment of gastric cancer with anti-egfr agents
ES2780948T3 (es) * 2013-07-11 2020-08-27 Scripps Research Inst Proteínas de fusión de inmunoglobulinas en hélice enrollada y composiciones de las mismas
AU2014348552A1 (en) 2013-11-13 2016-06-02 Zymeworks Inc. Monovalent antigen binding constructs targeting EGFR and/or HER2 and uses thereof
HUE047806T2 (hu) * 2014-08-29 2020-05-28 Hoffmann La Roche Kombinációs kezelés tumort célzó IL-2-variáns immuncitokinekkel és humán PD-L1 elleni antitestekkel
CN104991065B (zh) * 2015-07-07 2017-01-11 复旦大学附属金山医院 一种用于诊断乳腺癌的三联标志物及其应用
JP2018062980A (ja) * 2016-10-12 2018-04-19 株式会社ジェイテクト ボールネジ装置、ボールネジ装置の製造方法及びステアリング装置

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989006692A1 (en) * 1988-01-12 1989-07-27 Genentech, Inc. Method of treating tumor cells by inhibiting growth factor receptor function
AU4128089A (en) 1988-09-15 1990-03-22 Rorer International (Overseas) Inc. Monoclonal antibodies specific to human epidermal growth factor receptor and therapeutic methods employing same
AU658396B2 (en) 1991-03-06 1995-04-13 Merck Patent Gesellschaft Mit Beschrankter Haftung Humanized and chimeric monoclonal antibodies
AU675916B2 (en) * 1991-06-14 1997-02-27 Genentech Inc. Method for making humanized antibodies
US6410690B1 (en) * 1995-06-07 2002-06-25 Medarex, Inc. Therapeutic compounds comprised of anti-Fc receptor antibodies
US20030086924A1 (en) 1999-06-25 2003-05-08 Genentech, Inc. Treatment with anti-ErbB2 antibodies
WO2004032960A1 (en) 2002-10-10 2004-04-22 Merck Patent Gmbh Pharmaceutical compositions directed to erb-b1 receptors
CA2555791A1 (en) * 2004-02-12 2005-08-25 Merck Patent Gesellschaft Mit Beschraenkter Haftung Highly concentrated liquid formulations of anti-egfr antibodies
PE20070207A1 (es) * 2005-07-22 2007-03-09 Genentech Inc Tratamiento combinado de los tumores que expresan el her

Also Published As

Publication number Publication date
EP1968633B1 (en) 2014-02-12
CN101365486B (zh) 2012-10-31
EP1968633B2 (en) 2017-11-01
EA200870141A1 (ru) 2009-02-27
CN101365486A (zh) 2009-02-11
JP2009522316A (ja) 2009-06-11
WO2007076923A1 (en) 2007-07-12
CA2636074A1 (en) 2007-07-12
ZA200806723B (en) 2009-09-30
AU2006332212B2 (en) 2013-03-28
MX2008008564A (es) 2009-01-29
US20150132308A1 (en) 2015-05-14
BRPI0620888A2 (pt) 2011-11-29
AU2006332212B8 (en) 2013-05-30
KR20080110987A (ko) 2008-12-22
US20090214541A1 (en) 2009-08-27
AU2006332212A1 (en) 2007-07-12
US9522956B2 (en) 2016-12-20
EA015173B1 (ru) 2011-06-30
EP1968633A1 (en) 2008-09-17

Similar Documents

Publication Publication Date Title
AR059127A1 (es) Terapeutica combinada con anticuerpos anti-egfr y anti-her2
JP2017149720A5 (es)
PE20091474A1 (es) Anticuerpos monoclonales contra la proteina rgm a y sus usos
PE20100251A1 (es) Anticuerpos anti-5t4 humanizados y conjugados anticuerpo anti-5t4/calicheamicina
PE20081179A1 (es) Formulaciones estables de anticuerpos egfr
HRP20100521T1 (xx) Monoklonska antitijela protiv čimbenika rasta hepatocita
PE20141398A1 (es) Anticuerpos neutralizantes de citomegalovirus humano
NZ609619A (en) Novel egfr-binding molecules and immunoconjugates thereof
ES2523194T3 (es) Anticuerpo monoclonal humano específico para cada tumor
NZ578943A (en) Recombinant anti-epidermal growth factor receptor antibody compositions
PE20121023A1 (es) Anticuerpos e inmunoconjugados
JP2013091655A5 (es)
EA201190132A1 (ru) Гуманизированные антитела, связывающиеся с cd19, и их применение
AR047611A1 (es) Formulaciones liquidas de anticuerpos anti-egfr altamente concentradas
US10174116B2 (en) Antibody specifically binding to HER2
RU2016100892A (ru) Антитела против tweakr и их применение
PE20120079A1 (es) Moleculas de anticuerpos mejoradas
PA8650001A1 (es) Formulaciones de anticuerpo
IL277633D0 (en) Antibodies and methods of use
NZ594466A (en) Human monoclonal antibodies to protein tyrosine kinase 7 (PTK7) and methods for using anti-PTK7 antibodies
NZ568403A (en) CD20-specific antibodies and methods of employing same
AU2006332065A1 (en) Antibodies directed to HER-3 and uses thereof
MX9504802A (es) Anticuerpos anti-egfr y fvs de cadena simple anti-egfr.
PE20121579A1 (es) Proteinas de enlace al antigeno il-23 humanas
JP2017512759A5 (es)

Legal Events

Date Code Title Description
FB Suspension of granting procedure